cytokine News
-
Creative Proteomics Cytokine Unveils Disease Cytokine Assays for Disease Diagnosis
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced Disease Cytokine Assays to help researchers obtain higher quality scientific research data. Cytokines, ...
-
Creative Proteomics Cytokine Launches High-Sensitivity Inflammation Cytokines Assay to Support Your Research
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics is proud to announce the launch of the high-sensitivity inflammatory cytokine assays. These assays offer ultra-sensitivity, excellent ...
-
Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high sensitivity to support research in immune responses, inflammatory ...
-
Creative Proteomics Cytokine Unveils Tumor Necrosis Factors (TNF) Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced the launch of the high-sensitivity Tumor Necrosis Factors (TNF) Detection Service to help with your ...
-
Creative Proteomics Cytokine Boosts Cancer Research with Cancer Cytokines Assay
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company was pleased to announce the launch of its Cancer Cytokines Assay, assisting in the detection of multiple cytokine ...
-
Creative Proteomics Cytokine Announces Cytokine Systemic Lupus Erythematosus Cytokines Assay Solutions
Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative proteomics recently announced high sensitivity and wide detection range quantitative detection for systemic lupus erythematosus related cytokines ...
-
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) annual meeting in New Orleans taking place April 8–13, 2022. The abstract, titled “Driving anti-tumor activity in solid tumors with controlled arming of allogeneic CAR-NK cells,” details the Company’s efforts to ...
-
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022. The data to be presented outline next-generation advancements ...
-
Creative Proteomics Cytokine Accelerates Your Project with Its Colony Stimulating Factor Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced the launch of the colony stimulating factor detection platform for scientific research. ...
-
Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Research
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and ...
-
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP), to support the development of Orion’s lead compound, OB-002, a promising treatment for ...
-
Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform at the American Associate of Cancer Research (AACR) Annual Meeting 2022
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present data highlighting the potential of the company’s cytoDRiVE® platform technology, which allows regulation of protein expression using small molecule drugs. The data to be presented demonstrate tight control of membrane bound or shed IL12 (a proinflammatory ...
-
Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells
Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its study entitled “A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With ...
-
Creative Proteomics Cytokine Launches Growth Factors (GF) Detection Service for Your Research
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company is pleased to announce the launch of the growth factors (GF) detection service for further research enhancement. ...
-
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
NEW YORK, December 17, 2021 – Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the ...
-
AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer
Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, today announced the appointment of Djordje Filipovic, PhD, as Chief ...
By AB2 Bio Ltd.
-
Overview Of SFA Therapeutics
SFA Therapeutics’ CEO Dr Ira Spector presents an overview of the company and its platform technology SFA Overview Presentation on YouTube Introduction to SFA Liver Disease and Oncology Programs. SFA Oncology More information here We received US Patent 10,143,669B2; to prevent Hepatitis B progression to HCC, a liver cancer that affects 400 million patients and causes 1 million cancer ...
-
Valo Health Announces Publication of the Journal of Clinical Investigation of a New Therapeutic Approach to Improve CD8+ T Cell Function
Valo Health, Inc (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, announced a proof of concept for using its preclinical asset, OPL-0101, to target CD8+ T cells, in the ...
-
Creative Proteomics Cytokine Announces the Launch of Chemokine Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Chemokines Detection Service to help thoroughly investigate the many types of chemokines induced by ...
-
FRONTBIO Inc IND Approval for Phase 1 Clinical Trial for Eczema Treatment
FRONTBIO, a new drug development bio company, announced on the 5th that it had received approval from the Ministry of Food and Drug Safety on the 2th of last month for a phase 1 clinical trial (IND) for 'FB1A1,' a new drug candidate material under development for the treatment of eczema. FB1A1 treats eczema by normalizing the hypersensitive immune response caused by the imbalance of cytokines ...
By Frontbio
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you